A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis
Rhinitis, Allergic, Perennial
Bottom Line
View on ClinicalTrials.gov: NCT00682643 ↗Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- fluticasone furoate nasal spray (Drug); vehicle placebo nasal spray (Drug)
- Age
- Pediatric, Adult, Older Adult · 12+ yrs
- Sex
- All
- Sponsor
- GlaxoSmithKline
- Primary completion
- Feb 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cumulative Proportion (CU) of Participants (Par.) With an Event, as Measured as a Percentage, for Posterior Subcapsular Opacity (P) |
0.60; 0.88; 1.24; 1.84; 1.93; 2.56 | 0.395 |
| PRIMARY Cumulative Proportion of Participants, as Measured as a Percentage, With an Intraocular Pressure (IOP) Event |
0.00; 0.00; 0.00; 0.32; 0.00; 0.32 | 0.342 |
| SECONDARY Change From Baseline in LOCS III Posterior Subcapsular Opacity at Week 52 and Week 104 |
0.00; 0.00; 0.00; 0.00; 0.00; 0.00 | — |
| SECONDARY Number of Participants With the Indicated Change From Baseline in LOCS III Posterior Subcapsular Opacity by Increments of 0.1 at Weeks 52 and 104 |
0; 0; 0; 0; 2; 5 | — |
| SECONDARY Change From Baseline in LOCS III Cortical Opacity (C) at Week 52 and Week 104 |
0.01; 0.00; 0.02; 0.01; -0.01; 0.00 | — |
| SECONDARY Number of Participants With the Indicated Change From Baseline in Cortical Opacity by Increment Categories of >=0.3, >=0.5, and >=1.0 at Weeks 52 and 104 |
4; 4; 1; 0; 1; 0 | — |
| SECONDARY Change From Baseline in LOCS III Nuclear Opacity (NO) at Week 52 and Week 104 |
0.12; 0.06; 0.21; 0.10; 0.12; 0.06 | — |
| SECONDARY Change From Baseline in Nuclear Color (NC) at Week 52 and Week 104 |
0.14; 0.09; 0.21; 0.13; 0.16; 0.09 | — |
| SECONDARY Change From Baseline in Intraocular Pressure (IOP) at Weeks 52 and 104 |
-0.5; -0.3; -0.8; -0.6; -0.7; -0.4 | — |
| SECONDARY Number of Participants With the Indicated Change From Baseline in Intraocular Pressure (IOP) by Increments of 1 mm Hg at Week 52 |
1; 0; 0; 0; 0; 2 | — |
| SECONDARY Number of Participants With the Indicated Change From Baseline in Intraocular Pressure (IOP) by Increments of 1 mm Hg at Week 104 |
0; 0; 0; 1; 0; 0 | — |
| SECONDARY Change From Baseline in Logarithm of the Minimum Angle of Resolution (LogMAR) Visual Acuity (VA) Using Early Treatment Diabetic Retinopathy Study (ETDRS) Charts at Week 52 and Week 104 |
-0.027; -0.013; -0.035; -0.023; -0.023; -0.014 | — |
| SECONDARY Percent Change From Baseline in the Funduscopic Horizontal Cup-to-disc Ratio at Week 104 |
0.0; 0.7; 0.0; 0.0 | — |
| SECONDARY Change From Baseline in the Daily Reflective Total Nasal Symptom Score (rTNSS) for the Indicated Study Periods |
-2.12; -3.19; -2.52; -3.86; -2.56; -3.89 | — |
Summary
Eligibility Criteria
Inclusion Criteria
Subjects eligible for enrollment in the study must meet all of the following criteria:
- Informed consent
- Subject has provided an appropriately signed and dated informed consent. An appropriately signed and dated assent must be obtained from the parents or guardian if the subject is a child under 18 years of age.
- Outpatient
- Subject is treatable on an outpatient basis.
- Age
- 12 years of age and older at Visit 2
- Male or eligible female Female subjects should not be enrolled if they plan to become pregnant during the time of study participation.
To be eligible for entry into the study, females of childbearing potential must commit to the consistent and correct use of an acceptable method of birth control, as defined by the following:
- Abstinence Females of childbearing potential who are not sexually active must commit to complete abstinence from intercourse for two weeks before exposure to the study drug, throughout the clinical trial, and for a period after the trial to account for elimination of the drug (minimum of six days).
- Oral contraceptive (either combined estrogen/progestin or progestin only)
- Injectable progestogen
- Implants of levonorgestrel
- Percutaneous contraceptive patches
- Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year,
- Male partner who is sterile (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study and is the sole sexual partner for that female subject, or
- Double barrier method-condom or occlusive cap (diaphragm or cervical /vault caps) plus Spermicide,
- Estrogenic vaginal ring. A urine pregnancy test will be done at the screening visit to confirm females of childbearing potential are not pregnant upon entry into the study. In addition, urine pregnancy tests will be done for all females of childbearing potential at each clinic visit.
- Diagnosis of PAR to include:
A positive skin test (by prick method) response to appropriate perennial allergen (house dust mites, animal dander, mold, or cockroach) within last 12 months prior to Visit 1 or at Visit 1.
A positive skin test is defined as a wheal ³3mm larger than the diluent control for prick testing.
•Two year medical history and past treatment of PAR (written or verbal confirmation) which includes perennial, i.e., year-round, symptoms. PAR symptoms could include nasal congestion, rhinorrhea, nasal itching and sneezing.
In vitro tests for specific IgE (such as RAST, PRIST) will not be allowed for the diagnosis of PAR.
NOTE: Subjects who meet the above criteria and who also may have seasonal allergic rhinitis (SAR) and/or perennial non-allergic rhinitis (PNAR) are eligible for randomization.
- Environment
•Subject must be symptomatic to appropriate perennial allergen (animal dander, house dust mites, cockroach, mold) and willing to maintain, as much as possible, the same environment throughout the study.
- Ability to comply with study procedures Subject understands and is willing, able and likely to comply with study procedures and restrictions.
- Literate Subject must be able to read, comprehend, and record information in English
Exclusion Criteria
Subjects meeting any of the following criteria must not be enrolled in the study:
- Significant concomitant medical conditions, defined as but not limited to:
- A historical or current evidence of clinically significant uncontrolled disease of any body system (e.g., tuberculosis, psychological disorders, eczema). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or which would confound the interpretation of the study results if the disease/condition exacerbated during the study.
- History or current diagnosis of diabetes mellitus
- Uncontrolled hypertension (i.e., systolic blood pressure ³ 140mm Hg or diastolic blood pressure ³ 90mm Hg)
- A severe physic
Data sourced from ClinicalTrials.gov (NCT00682643). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.